VIENNA--(BUSINESS WIRE)--Miracor Medical Systems GmbH announced today that the Company’s CEO, Jon H. Hoem, will present Miracor Medical Systems and its breakthrough PICSO® System at the “Sixth Annual OneMedForm San Francisco” investor conference, Sir Francis Drake Hotel, San Francisco, on Wednesday, January 9, 2013, at 12:20 p.m. PST.
Earlier this week Miracor Medical announced that its PICSO® System was used for the first time under CE mark in the UK to treat a patient with a large acute heart attack (STEMI). Interventional cardiologist Dr. Magdi El-Omar performed the PICSO procedure at Manchester Royal Infirmary (Manchester, England). His patient, a 38-year-old female, has been discharged from the hospital. Also this week, Miracor’s PICSO® System was the focus of a December 2012 report by the UK’s National Institute for Health Research (NIHR) that cites PICSO as a key emerging health intervention whose potential impact “…to current treatments such as PCI (percutaneous coronary intervention, or angioplasty) could improve patient outcomes by reducing the damage to, or scarring of, the heart muscle.”
(Click here for video animation of PICSO®.)
About PICSO®
Timely myocardial reperfusion using primary percutaneous coronary intervention (PCI) remains the most effective treatment for limiting infarct size, reducing left ventricular remodeling, and improving clinical outcomes following ST-segment elevation myocardial infarction (STEMI). Despite optimum primary PCI, mortality and morbidity following a STEMI event remains sizable. Clearly, primary PCI alone is not enough to eliminate the risk for future cardiovascular events. Miracor’s Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO®) Impulse System offers a new and innovative approach to reduce myocardial injury and to revitalize ischemic myocardium. Initial clinical results show positive effects on MACE, restenosis rates, and long-term event-free survival. The PICSO® system consists of the Miracor PICSO® Impulse Console and the disposable, single-use Miracor PICSO® Impulse Catheter.
About Miracor Medical Systems GmbH
Based in Vienna, Austria, privately held Miracor is commercializing a unique and potentially disruptive technology, PICSO®, for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients. The Company’s objective is to establish PICSO® as the standard of care for heart attack patients, thereby improving their quality of life. The initial market opportunity for PICSO® is 40% of all ACS patients treated per year, which translates into more than 350,000 patients in the U.S. and Europe. The Miracor PICSO® Impulse System is CE-marked and can be used during coronary revascularization procedures following myocardial infarction and other types of acute coronary syndromes to intermittently increase the pressure in the coronary venous system. The technology is for investigational use only in the United States at this time.